CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Saxagliptin + Metformin

Saxagliptin + Metformin

Last Updated: August 23, 2013

Result type: Reports

Project Number: SR0348-000

Product Line: Reimbursement Review

Generic Name: Saxagliptin + metformin

Brand Name: Komboglyze

Manufacturer: AstraZeneca Canada Inc.

Therapeutic Area: Diabetes Mellitus, type 2

Indications: Diabetes Mellitus, Type 2

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 20, 2014

Recommendation Type: List with criteria/condition

Saxagliptin + Metformin

Files